Skip to main content
Top of the Page

SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO’s mission is to expedite worldwide research and education through the exchange of scientific information.

Learn more »

SOHO represents physicians and other professionals from all corners of the world. SOHO is leading vital efforts to further treatments for those with hematologic malignancies. Become a SOHO Member free-of-charge. Join us and experience the benefits of membership.

Join Now

The Society of Hematologic Oncology (SOHO) holds its annual meeting during the September timeframe of each year in Houston, Texas. Note that SOHO members receive a 40% discount on registration fees. We expect approximately 2,500 hematologic oncology specialists to participate in the upcoming Tenth Annual Meeting of the Society (SOHO 2022). Click for more information and registration.

Register now
  • 6,153 members strong

Join Us Today and Become a Part of the SOHO Community

Benefits of membership include:
  • Instant connections to our SOHO Community of nearly 6,000 members
  • Access to a comprehensive Resource Center that includes slides, publications, abstracts, videos & more
  • Connection to our SOHO DocMatter Community for hematologic oncology discussions and education
  • Free online access to our official journal, ‘Clinical Lymphoma Myeloma and Leukemia
  • Free online and print subscription to our news publication, 'Blood Cancers Today'
  • Significant member-only discounts on meetings and events
  • Early member-only registration and housing opportunities
  • ... and much more!

Ambassador Program

The Ambassador Program was created to increase geographical diversity and promote international understanding among hematologic oncology experts around the world. If you are interested, Contact us!

Latest News

Liso-Cel Outperforms Standard of Care as Second-Line Treatment for R/R LBCL

The phase III TRANSFORM trial demonstrated the superiority of liso-cel as a second-line treatment for early R/R LBCL.

Bendamustine Effective for Lymphodepletion Before Tisagenlecleucel in Patients with R/R LBCL

Bendamustine for lymphodepletion before tisagenlecleucel has an efficacy similar to fludarabine/cyclophosphamide in this patient population.

Triplet Regimen Plus AHSCT Boosts PFS in Adults with MM

This combo plus lenalidomide maintenance resulted in significantly improved PFS in patients with newly diagnosed MM.

FDA Grants Orphan Drug Designation to Masked Immunocytokine QXL138AM for MM

The FDA granted Orphan Drug Designation to masked immunocytokine QXL138AM for the treatment of myeloma.

PARP Inhibitors Increase Risk for MDS, AML

Treatment with PARP inhibitors may come with an elevated real-world risk of MDS or AML.

Phase I Study of Anbal-Cel CD19 CAR-T Treatment Demonstrates Response in Relapsed/Refractory LBCL

A single dose of anbalcabtagene autoleucel induced an 82% complete remission rate in patients with relapsed/refractory large B-cell lymphoma.

Novel BCL2 Inhibitor Induces Responses in Relapsed/Refractory Disease

Lisaftoclax induced responses in patients with a variety of relapsed/refractory malignancies, including NHL and CLL.

"Very interesting and exciting to share ideas and data with other hem/onc clinicians and scientists from around the world"
–Prof. Dieter Hoelzer, founding member
Back to Top